Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
Neuroendocrine Tumors
DEVICE: PET/CT Imaging|RADIATION: 68Ga-DOTA-JR11|RADIATION: 177Lu-DOTA-JR11
Overall Response Rate (ORR), according to RECIST 1.1 and median progression-free and overall survival will be estimated and reported with 95% confidence intervals, 2 years
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).